Linked Life Data

20515942

Source:http://linkedlifedata.com/resource/pubmed/id/20515942

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20515942rdf:typepubmed:Citationlld:pubmed
pubmed-article:20515942lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0677626lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0600388lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0041904lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C1336644lld:lifeskim
pubmed-article:20515942lifeskim:mentionsumls-concept:C0054245lld:lifeskim
pubmed-article:20515942pubmed:issue6lld:pubmed
pubmed-article:20515942pubmed:dateCreated2010-6-11lld:pubmed
pubmed-article:20515942pubmed:abstractTextTumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death in various types of cancer cells but has little or no effect on normal cells. Human hepatoma cells are resistant to TRAIL-induced apoptosis. Although butein is known to mediate anticancer, anti-inflammatory, and antioxidant activities, little is known about the mechanism of butein in terms of TRAIL-induced apoptosis of human hepatoma cells. In this study, we determined that butein enhances TRAIL-induced apoptosis in hepatoma cells through upregulation of DR5. Luciferase analysis showed that a 5'-flanking region containing four Sp1-binding sites within the DR5 promoter was enhanced by butein (-305/-300). Electrophoretic mobility shift assays and chromatin immunoprecipitation studies were used to analyze the elevation of Sp1 binding to DR5 promoter sites by butein. Point mutations of the Sp1-binding site also attenuated promoter activity. Furthermore, pretreatment of the blocking chimeric antibody and small interfering RNA for DR5 significantly suppressed TRAIL-mediated apoptosis by butein in Hep3B cells. Butein also stimulated extracellular signal-regulated kinase (ERK) activation, and the ERK inhibitor PD98059 blocked butein-induced DR5 expression and suppressed binding of Sp1 to the DR5 promoter. Additionally, generation of reactive oxygen species had no effect on cell viability, although pretreatment with N-acetyl-l-cysteine or glutathione inhibited combined treatment-induced reactive oxygen species. Indeed, butein repressed the TRAIL-mediated activation of NF-kappaB and decreased its transcriptional activity. Our results suggest that butein could sensitize certain human hepatoma cells to TRAIL-induced apoptosis through stimulating its death signaling and by repressing the survival function in these cells.lld:pubmed
pubmed-article:20515942pubmed:languageenglld:pubmed
pubmed-article:20515942pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:citationSubsetIMlld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20515942pubmed:statusMEDLINElld:pubmed
pubmed-article:20515942pubmed:monthJunlld:pubmed
pubmed-article:20515942pubmed:issn1538-8514lld:pubmed
pubmed-article:20515942pubmed:authorpubmed-author:ChoiYung...lld:pubmed
pubmed-article:20515942pubmed:authorpubmed-author:KimGi-YoungGYlld:pubmed
pubmed-article:20515942pubmed:authorpubmed-author:MoonDong-OhDOlld:pubmed
pubmed-article:20515942pubmed:authorpubmed-author:KimMun-OckMOlld:pubmed
pubmed-article:20515942pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20515942pubmed:volume9lld:pubmed
pubmed-article:20515942pubmed:ownerNLMlld:pubmed
pubmed-article:20515942pubmed:authorsCompleteYlld:pubmed
pubmed-article:20515942pubmed:pagination1583-95lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:meshHeadingpubmed-meshheading:20515942...lld:pubmed
pubmed-article:20515942pubmed:year2010lld:pubmed
pubmed-article:20515942pubmed:articleTitleButein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.lld:pubmed
pubmed-article:20515942pubmed:affiliationLaboratory of Immunobiology, Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea.lld:pubmed
pubmed-article:20515942pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20515942pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed